|
|
"RNAi Synthetic Lethal Screen in Cancer Cell Models."
|
N44CO120065-000
|
$999,596
|
$329,867
|
CHENCHIK, ALEXANDR
|
CELLECTA, INC.
|
|
|
(OTHER FUNCTIONS) OBTAIN TREATMENT AND MORTALITY DATA FROM ERSPC
|
N02CA120380-000
|
$90,000
|
$90,000
|
ROOBOL, MONIQUE
|
ERASMUS MEDICAL CENTER
|
|
|
13C DIM REPRESSES ANDROGEN-INDUCED TWIST 1 EXPRESSION IN HUMAN PROSTATE CANCER
|
Y01CN129005
|
$68,000
|
$34,000
|
UNKNOWN, UNKNOWN
|
U.S. NATIONAL INSTITUTES OF HEALTH
|
|
|
15-Lipoxygenase-2 (ALOX15B) as a Tumor Suppressor
|
5R01CA131445-05
|
$214,879
|
$214,879
|
NIE, DAOTAI
|
SOUTHERN ILLINOIS UNIVERSITY SCH OF MED
|
|
|
A Cellular and Molecular Analysis of the Intravasation Step in Tumor Metastasis
|
5R01CA129484-05
|
$381,417
|
$95,354
|
QUIGLEY, JAMES
|
SCRIPPS RESEARCH INSTITUTE
|
|
|
A metabolic role for PML in tumor suppression
|
5R01CA142780-03
|
$350,219
|
$87,555
|
PANDOLFI, PIER PAOLO
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
|
|
A Mitogen-induced G Protein-coupled Receptor
|
ZIASC009389
|
$123,443
|
$61,722
|
Kelly, Kathleen
|
CCR (NCI)
|
|
|
A Multi-State Study of Cancer Treatment and Outcomes Among American Indians
|
5R01CA125231-06
|
$374,097
|
$56,115
|
RAMSEY, SCOTT
|
FRED HUTCHINSON CANCER RESEARCH CENTER
|
|
|
A MULTILEVEL APPROACH TO ENERGY BALANCE AND CANCER ACROSS THE LIFECOURSE
|
5U54CA155496-02
|
$1,712,824
|
$479,591
|
COLDITZ, GRAHAM
|
WASHINGTON UNIVERSITY
|
|
|
A Nanotechnology Enabled Diagnostic Platform for Early Stage Cancer Detection
|
5R44CA143232-03
|
$749,659
|
$749,659
|
Nelson, James
|
INANOVATE, INC.
|
|
|
A Network Analytic Approach to Modeling Variation in Prostate Cancer Care
|
5K07CA151910-02
|
$156,570
|
$156,570
|
Pollack, Craig
|
JOHNS HOPKINS UNIVERSITY
|
|
|
A new regulator for Wnt/beta-catenin signaling and prostate tumorigenesis
|
5R01CA151623-02
|
$336,257
|
$336,257
|
SUN, ZIJIE
|
STANFORD UNIVERSITY
|
|
|
A Novel Mechanism for Control of Androgen Receptor Levels in HRPC
|
5R01CA138583-02
|
$280,125
|
$280,125
|
HAMBURGER, ANNE
|
UNIVERSITY OF MARYLAND BALTIMORE
|
|
|
A novel mouse prostate carcinogenesis model for dietary cancer prevention researc
|
1R03CA159361-01A1
|
$77,333
|
$77,333
|
Li, Guangxun
|
RUTGERS THE ST UNIV OF NJ NEW BRUNSWICK
|
|
|
A Novel Synthetic Androgen Receptor Antagonist
|
5R01CA131137-05
|
$313,989
|
$313,989
|
DONG, ZHONGYUN
|
UNIVERSITY OF CINCINNATI
|
|
|
A Novel Therapeutic Approach for Primary and Metastatic Prostate Cancer
|
5R01CA150182-02
|
$293,483
|
$293,483
|
AHMED, KHALIL
|
UNIVERSITY OF MINNESOTA
|
|
|
A Platform for Cancer Biomarker Validation: Image Fusion Using NIR Fluorescence
|
5R01CA134493-04
|
$688,070
|
$688,070
|
Frangioni, John
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
|
|
A Role of Novel Serpin Maspinin Prostate Tumor/Bone Interaction
|
5R01CA127735-05
|
$302,919
|
$302,919
|
SHENG, SHIJIE
|
WAYNE STATE UNIVERSITY
|
|
|
A Systems Biology Approach to the Development of Cancer Biomarkers
|
5U01CA111275-08
|
$685,047
|
$685,047
|
CHINNAIYAN, ARUL
|
UNIVERSITY OF MICHIGAN AT ANN ARBOR
|
|
|
A Systems Genetics Analysis of Cancer Risk, Progression and Therapeutic Response
|
5U01CA084244-14
|
$759,738
|
$151,948
|
BALMAIN, ALLAN
|
UNIVERSITY OF CALIFORNIA-SAN FRANCISCO
|
|
|
A+PSA Assay for Improved Prostate Cancer Diagnosis and Risk Assessment
|
1R01CA164388-01
|
$319,550
|
$319,550
|
Zeng, Gang
|
UNIVERSITY OF CALIFORNIA AT LOS ANGELES
|
|
|
A+PSA Assay for Improved Prostate Cancer Diagnosis and Risk Assessment
|
3R01CA164388-01S1
|
$47,142
|
$47,142
|
Zeng, Gang
|
UNIVERSITY OF CALIFORNIA AT LOS ANGELES
|
|
|
AARP prospective study of diet and cancer
|
ZIA CP010196-03152
|
$1,258,475
|
$62,924
|
Sinha, Rashmi
|
DCEG (NCI)
|
|
|
Abramson Cancer Center Support Grant
|
5P30CA016520-36
|
$7,725,062
|
$231,752
|
DANG, CHI
|
UNIVERSITY OF PENNSYLVANIA
|
|
|
Ack1: A Critical Regulator of Hormone-Refractory Prostate Cancer
|
5R01CA135328-03
|
$328,495
|
$328,495
|
Mahajan, Nupam
|
H. LEE MOFFITT CANCER CTR & RES INST
|
|
|
Ack1: Activation and Consequences in Prostate Cancer
|
5R01CA120304-04
|
$296,195
|
$296,195
|
EARP, HENRY
|
UNIVERSITY OF NORTH CAROLINA CHAPEL HILL
|
|
|
ACOSOG Community Clinical Oncology Program (CCOP) Research Base
|
5U10CA149950-02
|
$1,474,780
|
$147,478
|
Sloan, Jeff
|
MAYO CLINIC
|
|
|
Adaptable Polymer Micelles for Tumor Targeting
|
5R01CA129287-03
|
$299,829
|
$149,915
|
PARK, KINAM
|
PURDUE UNIVERSITY WEST LAFAYETTE
|
|
|
Adiposity and Outcomes of Clinically Localized Prostate Cancer
|
5R01CA129140-04
|
$569,690
|
$569,690
|
Freeman, Vincent
|
UNIVERSITY OF ILLINOIS
|
|
|
Advanced Development of An Integrated CTC Enrichment Technology
|
5R33CA157396-02
|
$228,724
|
$228,724
|
TSENG, HSIAN-RONG
|
UNIVERSITY OF CALIFORNIA AT LOS ANGELES
|
|
|
Advanced PET/CT Imaging for Improving Clincail Trials
|
5U01CA148131-03
|
$562,213
|
$281,107
|
KINAHAN, PAUL
|
UNIVERSITY OF WASHINGTON
|
|
|
Advancement and Validation of Prostate Diffusion and Spectroscopic MRI
|
1R01CA160902-01A1
|
$408,667
|
$408,667
|
MAIER, STEPHAN
|
BRIGHAM AND WOMEN'S HOSPITAL
|
|
|
Aging and Prostate Cancer Risk--the Role of T Cell Dysfunction
|
5R03CA156404-02
|
$77,000
|
$77,000
|
DE GRAFFENRIED, LINDA
|
UNIVERSITY OF TEXAS AUSTIN
|
|
|
Alternative splicing and epithelial-mesenchymal plasticity in prostate tumors
|
5R01CA127727-04
|
$313,989
|
$313,989
|
Garcia-Blanco, Mariano
|
DUKE UNIVERSITY
|
|
|
Amoeboid Membrane Dynamics in Prostate Cancer
|
7R01CA143777-03
|
$396,473
|
$396,473
|
FREEMAN, MICHAEL
|
CEDARS-SINAI MEDICAL CENTER
|
|
|
An androgen receptor coactivator regulated in prostate
|
5R01CA112226-05
|
$341,161
|
$341,161
|
LOGAN, SUSAN
|
NEW YORK UNIVERSITY SCHOOL OF MEDICINE
|
|
|
An androgen-regulated cytokine network controls prostate apoptosis
|
7R01CA151753-02
|
$318,513
|
$318,513
|
KROLEWSKI, JOHN
|
UNIVERSITY OF ROCHESTER
|
|
|
An Interactive E-Health Program to Promote Health Behaviors among Cancer Survivor
|
5R03CA142042-02
|
$92,236
|
$31,360
|
KREBS, PAUL
|
NEW YORK UNIVERSITY SCHOOL OF MEDICINE
|
|
|
Analyses of human T regulatory cells
|
ZIABC010973
|
$268,098
|
$80,429
|
Tsang, Kwong
|
CCR (NCI)
|
|
|
Analysis of Lag-3 in Regulatory T Cell Function and Immune Supression
|
5R01CA127153-05
|
$330,091
|
$165,046
|
DRAKE, CHARLES
|
JOHNS HOPKINS UNIVERSITY
|
|
|
Androgen Receptor Function in Prostate Cancer
|
3R01CA086072-10S1
|
$77,500
|
$77,500
|
PESTELL, RICHARD
|
THOMAS JEFFERSON UNIVERSITY
|
|
|
Androgen Receptor Function in Prostate Cancer
|
5R01CA086072-10
|
$310,970
|
$310,970
|
PESTELL, RICHARD
|
THOMAS JEFFERSON UNIVERSITY
|
|
|
Androgen Receptor Regulation by Phosphorylation
|
5R00CA135592-04
|
$241,529
|
$241,529
|
Chen, Shaoyong
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
|
|
Androgen Receptor Targeted Vaccines for Prostate Cancer
|
5R01CA142608-03
|
$304,715
|
$304,715
|
MCNEEL, DOUGLAS
|
UNIVERSITY OF WISCONSIN-MADISON
|
|
|
Androgen Receptor-JunD Complex Inhibitors to Prevent Prostate Cancer Progression
|
1R43CA162734-01A1
|
$300,000
|
$300,000
|
BASU, HIRAK
|
COLBY PHARMACEUTICAL COMPANY
|
|
|
Androgen Signaling and Coactivator Regulation in PCA
|
5R01CA150197-03
|
$309,544
|
$309,544
|
Kung, Hsing-Jien
|
UNIVERSITY OF CALIFORNIA DAVIS
|
|
|
Anti-Tumor Mechanisms and Therapeutic Effects of Vitamin D
|
5R01CA067267-18
|
$430,613
|
$142,102
|
JOHNSON, CANDACE
|
ROSWELL PARK CANCER INSTITUTE CORP
|
|
|
Anticancer Agents from Plant- and Lichen-Associated Fungi of the Sonoran Desert
|
4R01CA090265-08
|
$263,534
|
$65,884
|
GUNATILAKA, LESLIE
|
UNIVERSITY OF ARIZONA
|
|
|
ANTICANCER DRUG DISCOVERY THAT TARGETS TUMOR HYPOXIA
|
5R01CA098787-08
|
$262,130
|
$65,533
|
NAGLE, DALE
|
UNIVERSITY OF MISSISSIPPI
|
|
|
Anticarcinogenic Effect of ITCs Against Prostate Cancer
|
5R01CA101753-09
|
$319,332
|
$319,332
|
Singh, Shivendra
|
UNIVERSITY OF PITTSBURGH AT PITTSBURGH
|
|
Total relevant funding to Prostate for this search: $265,094,495
|
